Publications by authors named "Michael Looby"

Claim this Profile
A
A framework to guide dose & regimen strategy for clinical drug development.
Oliver Sander, Baldur Magnusson, Inga Ludwig, Astrid Jullion, Christophe Meille, Michael Looby

CPT Pharmacometrics Syst Pharmacol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimands-What they are and why they are important for pharmacometricians.
Mouna Akacha, Christian Bartels, Björn Bornkamp, Frank Bretz, Neva Coello, Michael Looby

CPT Pharmacometrics Syst Pharmacol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benchmarking QSP Models Against Simple Models: A Path to Improved Comprehension and Predictive Performance.
Andrew M Stein, Michael Looby

CPT Pharmacometrics Syst Pharmacol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach.
Christian Bartels, Michael Looby, Romain Sechaud, Guenther Kaiser

Br J Clin Pharmacol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel model-based approach for dose determination of glycopyrronium bromide in COPD.
Helen Arievich, Tim Overend, Didier Renard, Michael Gibbs, Vijay Alagappan, Michael Looby

BMC Pulm Med· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment on the report "limitations of model-based dose selection for indacaterol in patients with chronic obstructive pulmonary disease".
Michael Looby, Didier Renard, Andrew Wright, David Morris, Donald Stanski

Int J Clin Pharmacol Ther· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of fingolimod phosphate in healthy participants.
Kai Wu, Francois Mercier, Olivier J David, Robert L Schmouder, Michael Looby

J Clin Pharmacol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches.
Didier Renard, Michael Looby, Benjamin Kramer, David Lawrence, David Morris

Respir Res· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacodynamic model of the longitudinal FEV1 response to an inhaled long-acting anti-muscarinic in COPD patients.
Kai Wu, Michael Looby, Goonaseelan Pillai, Gregory Pinault, Anton Franz Drollman

J Pharmacokinet Pharmacodyn· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and optimal design of paediatric studies for famciclovir.
Kayode Ogungbenro, Ivan Matthews, Michael Looby, Guenther Kaiser, Gordon Graham

Br J Clin Pharmacol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of lumiracoxib in plasma and synovial fluid.
Graham Scott, Christiane Rordorf, Christine Reynolds, Jyoti Kalbag, Michael Looby

Clin Pharmacokinet· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis